What elevates the GPS™ test above other tests?
Tissue-based genomic assays vary in their validation data to predict long-term and short-term outcomes. They also differ in the ability of their results to help guide the active surveillance decision in low-risk and favorable intermediate-risk patients.
The only assay designed for critical treatment decisions in clinically low-risk, early-stage prostate cancer
Bring together biology, validation, and endpoint insights to soar above the competition:
*Studies performed in biopsy samples from clinically low risk and/or AS-candidate patient cohorts
**GPS Validation Studies